Results 151 to 160 of about 18,455 (220)

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [PDF]

BMC Cancer
Puranik AD, Dev ID, Yadav S, Rangarajan V, Agrawal A, Basu S, Chaudhari VA, Ramaswamy A, Ostwal V, Bhandare MS, Shrikhande SV, Parghane RV, Bhargava P, Bal MM, Yadav S, Patkar S, Goel M, Purandare NC, Shah S, Choudhury S, Ghosh S, Venkatachalam M.   +21 more
europepmc   +1 more source

Editorial: Women in radionuclide therapy: 2023

Frontiers in Nuclear Medicine
Egesta Lopci, Federica Matteucci
doaj   +1 more source

Neoadjuvant therapy with peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours. [PDF]

Br J Surg
Hallet J, Søreide K.
europepmc   +1 more source

Retraction: Efficacy and Safety of Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Comparative Studies. [PDF]

Cureus
Zhao J, Pei X, Li Y.
europepmc   +1 more source

Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours. [PDF]

J Neuroendocrinol
Kuiper J, Zoetelief E, Brabander T, de Herder WW, Hofland J.   +4 more
europepmc   +1 more source

Radiopharmaceutical formulation and preliminary clinical dosimetry of [¹⁷⁷Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy. [PDF]

Eur J Nucl Med Mol Imaging
Zavvar TS, Hörmann AA, Konijnenberg M, Kraihammer M, Mair C, Kronthaler A, Joosten L, Laverman P, Gruber L, di Santo G, Decristoforo C, Virgolini I, von Guggenberg E.   +12 more
europepmc   +1 more source

Preclinical Investigation of [²¹²Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model. [PDF]

J Nucl Med
Saidi A, Stallons TA, Wong AG, Torgue JJ.   +3 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Gujarathi R, Tobias J, Abou Azar S, Keutgen XM, Liao CY.   +4 more
europepmc   +1 more source

The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy. [PDF]

J Nucl Med
Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R, Bergsland EK, Hope TA.   +6 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival. [PDF]

Cancers (Basel)
Perrone E, Calcagni ML, Leccisotti L, Moretti R, Ghai K, Eismant A, Parkar T, Greifenstein L, Baum RP.   +8 more
europepmc   +1 more source